These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O; Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640 [TBL] [Abstract][Full Text] [Related]
44. Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET. Kim SJ; Ham H; Park YH; Choe YS; Kim YJ; Jang H; Na DL; Kim HJ; Moon SH; Seo SW Alzheimers Res Ther; 2022 Oct; 14(1):157. PubMed ID: 36266688 [TBL] [Abstract][Full Text] [Related]
45. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264 [TBL] [Abstract][Full Text] [Related]
51. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease. Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265 [TBL] [Abstract][Full Text] [Related]
52. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035 [TBL] [Abstract][Full Text] [Related]
53. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease. Villemagne VL; Rowe CC J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919 [TBL] [Abstract][Full Text] [Related]
54. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ; Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897 [TBL] [Abstract][Full Text] [Related]
55. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601 [TBL] [Abstract][Full Text] [Related]
56. Software development for quantitative analysis of brain amyloid PET. Matsuda H; Yamao T Brain Behav; 2022 Mar; 12(3):e2499. PubMed ID: 35134278 [TBL] [Abstract][Full Text] [Related]
57. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415 [TBL] [Abstract][Full Text] [Related]